Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS) is a biopharmaceutical company focused on the discovery and development of antiviral therapies. The company’s primary focus has centered on hepatitis B virus (HBV) infection, where it pursues both direct antivirals and immunotherapeutic approaches aimed at achieving functional cure in chronic hepatitis B patients.
What the company does
Arbutus Biopharma develops antiviral drug candidates targeting hepatitis B, an infectious disease affecting hundreds of millions of people globally. The company’s approach combines direct-acting antivirals that inhibit HBV replication with immunotherapy candidates designed to restore immune control over the virus. The goal is to move beyond suppression to functional cure, where patients achieve sustained virological control after stopping therapy.
How it makes money
As a clinical-stage biopharmaceutical company, Arbutus operates primarily through capital markets and licensing partnerships rather than product sales. The company may generate near-term revenue from collaborations with larger pharmaceutical firms seeking to access its hepatitis B pipeline or technology platform. Long-term revenue will depend on successful development and commercialization of antiviral candidates.
Where it sits in its industry
Arbutus competes with large pharmaceutical companies, other biotech firms, and academic research groups pursuing hepatitis B treatments and cures. The commercial opportunity is substantial given the large patient population and unmet medical need, but development risk is also high. Competitors include both those pursuing HBV directly and those developing platform antiviral technologies applicable to multiple viruses.
Development approach
The company’s competitive position depends on the efficacy and safety profile of its antiviral and immunotherapy candidates, speed of clinical development, intellectual property protection, and success in securing partnerships or funding. Hepatitis B cure represents an aspirational endpoint in viral infectious disease, comparable to successful programs in hepatitis C or HIV.
How to research it
Stakeholders can access Arbutus’s 10-K annual reports and 10-Q quarterly filings through the SEC’s EDGAR database. These documents disclose clinical trial updates, collaboration agreements, cash position, and R&D progress. Virology and infectious disease medical literature provides scientific context for understanding the company’s therapeutic approaches and competitive landscape.